2 recruiting, 1 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Terminated 1 |
Follow Peritoneal Mesothelioma: new trials by email Literature Review of Peritoneal Mesothelioma trials Research Report on Peritoneal Mesothelioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors IDE892, IDE397 - NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC) | Phase 1 | Recruiting | IDEAYA Biosciences | 260 | 2026-03-04 | 2026-09-28 |
| Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies Sodium Thiosulfate, 5-Fluorouracil, Oxaliplatin - Peritoneal Mesothelioma, Peritoneal Carcinomatosis | Phase 1 | Recruiting | National Cancer Institute (NCI) | 60 | 2021-10-19 | 2026-11-03 |
| Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma MCY-M11, Cyclophosphamide - Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma | Phase 1 | Terminated | MaxCyte, Inc. | 14 | 2018-08-27 | 2021-09-05 |
Adenocarcinoma Of Esophagus (1) · Appendiceal Neoplasms (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Gastrointestinal Neoplasms (1) · Mesothelioma (1) · Mesothelioma, Malignant (1) · Necrosis (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Peritoneal Neoplasms (1) · Recurrence (1) · Urinary Bladder Neoplasms (1)
Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Gastrointestinal Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Abdominal Neoplasms (1) · Adenoma (1)
Cisplatin (1) · Cyclophosphamide (1) · Doxorubicin (1) · Fluorouracil (1) · Mitomycin (1) · Oxaliplatin (1) · sodium thiosulfate (1)
IDEAYA Biosciences (1) · MaxCyte, Inc. (1) · National Cancer Institute (NCI) (1)
United States (3)
Andrew M Blakely, M.D. (1) · Claudio Dansky Ullmann, MD (1) · Edward Chan, MD (1)